Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 10
1947 10
1948 13
1949 12
1950 15
1951 16
1952 20
1953 19
1954 12
1955 20
1956 9
1957 9
1958 10
1959 8
1960 9
1961 7
1962 7
1963 5
1964 7
1965 2
1966 7
1967 9
1968 9
1969 15
1970 11
1971 18
1972 12
1973 13
1974 25
1975 50
1976 52
1977 38
1978 49
1979 51
1980 63
1981 61
1982 57
1983 76
1984 80
1985 56
1986 62
1987 60
1988 57
1989 47
1990 43
1991 45
1992 58
1993 34
1994 38
1995 34
1996 32
1997 26
1998 35
1999 32
2000 20
2001 23
2002 22
2003 25
2004 14
2005 16
2006 14
2007 14
2008 23
2009 17
2010 18
2011 19
2012 27
2013 22
2014 11
2015 22
2016 28
2017 13
2018 14
2019 18
2020 24
2021 22
2022 15
2023 26
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

2,016 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean segler (91 results)?
The PROMISE study: PROphylaxis of MIgraine with SEglor (dihydroergotamine mesilate) in French primary care.
Pradalier A, Lantéri-Minet M, Géraud G, Allain H, Lucas C, Delgado A. Pradalier A, et al. CNS Drugs. 2004;18(15):1149-63. doi: 10.2165/00023210-200418150-00009. CNS Drugs. 2004. PMID: 15581385 Clinical Trial.
INTRODUCTION: Seglor capsules, a unique modified-release formulation of dihydroergotamine mesilate, have long been in clinical use in France for migraine prophylaxis. The aim of the PROMISE (PROphylaxis of MIgraine with SEglor) study was to establish the effi …
INTRODUCTION: Seglor capsules, a unique modified-release formulation of dihydroergotamine mesilate, have long been in clinical …
Everything old is new again.
Freitag FG. Freitag FG. Headache. 2021 Sep;61(8):1286. doi: 10.1111/head.14181. Epub 2021 Aug 5. Headache. 2021. PMID: 34350590 No abstract available.
Dihydroergotamine-erythromycin-induced ergotism.
Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Leroy F, et al. Ann Intern Med. 1988 Aug 1;109(3):249. doi: 10.7326/0003-4819-109-3-249_1. Ann Intern Med. 1988. PMID: 3389610 No abstract available.
[Drug-induced headache].
Wallasch TM. Wallasch TM. Fortschr Neurol Psychiatr. 1992 Mar;60(3):114-8. doi: 10.1055/s-2007-999130. Fortschr Neurol Psychiatr. 1992. PMID: 1349547 Review. German.
Treatment of orthostatic hypotension.
Christensen NJ, Hilsted J. Christensen NJ, et al. Clin Physiol. 1985;5 Suppl 5:94-6. Clin Physiol. 1985. PMID: 3914392 Review. No abstract available.
Dihydroergotamine nasal spray.
Gijsman HJ, Ferrari MD. Gijsman HJ, et al. Neurology. 1995 Feb;45(2):397-8. doi: 10.1212/wnl.45.2.397-b. Neurology. 1995. PMID: 7854552 No abstract available.
Orally inhaled dihydroergotamine: a review.
Tepper SJ. Tepper SJ. Headache. 2013 Sep;53 Suppl 2:43-53. doi: 10.1111/head.12184. Headache. 2013. PMID: 24024602 Review.
Orally inhalable dihydroergotamine (iDHE), before the US Food and Drug Administration in 2013 for consideration for approval for acute treatment of episodic migraine in adults, is a user-friendly formulation of an older medication. Dihydroergotamine (DHE) has a hete …
Orally inhalable dihydroergotamine (iDHE), before the US Food and Drug Administration in 2013 for consideration for approval for acut …
The pharmacology of ergotamine and dihydroergotamine.
Silberstein SD. Silberstein SD. Headache. 1997;37 Suppl 1:S15-25. Headache. 1997. PMID: 9009470 Review.
Ergotamine tartrate (ET) was one of the first ergot alkaloids to be isolated. Dihydroergotamine (DHE) is synthesized by reducing an unsaturated bond in ergotamine (E); this modification results in a changed pharmacologic profile. Dihydroergotamine exhibits greater a …
Ergotamine tartrate (ET) was one of the first ergot alkaloids to be isolated. Dihydroergotamine (DHE) is synthesized by reducing an u …
What's new in the migraine attack treatment.
Lanteri-Minet M. Lanteri-Minet M. Rev Neurol (Paris). 2013 May;169(5):436-41. doi: 10.1016/j.neurol.2013.03.006. Epub 2013 Apr 18. Rev Neurol (Paris). 2013. PMID: 23602496 Review.
This short review aims to give a focus on news in the migraine attack treatment and discusses the CGRP receptor antagonists (gepants), the 5-HT1F receptors agonists (ditans), the transcranial magnetic stimulation for the treatment of migraine attack with aura, innovative delivery …
This short review aims to give a focus on news in the migraine attack treatment and discusses the CGRP receptor antagonists (gepants), the 5 …
2,016 results